Terms: = Leukemia AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Prognosis
25 results:
1. A Coumarin-Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting hsp90 and Its Client Proteins.
Nirgude S; Shahana M V ; Ravindran F; Kumar S; Sharma S; Mahadeva R; Mhatre A; Karki SS; Choudhary B
Molecules; 2023 Jul; 28(13):. PubMed ID: 37446888
[TBL] [Abstract] [Full Text] [Related]
2. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
3. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid leukemia.
Katagiri S; Chi S; Minami Y; Fukushima K; Shibayama H; Hosono N; Yamauchi T; Morishita T; Kondo T; Yanada M; Yamamoto K; Kuroda J; Usuki K; Akahane D; Gotoh A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563085
[TBL] [Abstract] [Full Text] [Related]
4. Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance.
Fleischmann M; Fischer M; Schnetzke U; Fortner C; Kirkpatrick J; Heidel FH; Hochhaus A; Scholl S
Cells; 2021 Nov; 10(11):. PubMed ID: 34831215
[TBL] [Abstract] [Full Text] [Related]
5. Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid leukemia.
Freisleben F; Modemann F; Muschhammer J; Stamm H; Brauneck F; Krispien A; Bokemeyer C; Kirschner KN; Wellbrock J; Fiedler W
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639011
[TBL] [Abstract] [Full Text] [Related]
6. hsp90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
[TBL] [Abstract] [Full Text] [Related]
7. Interaction network of proteins associated with unfavorable prognosis in acute myeloid leukemia.
Rendon-Rodriguez JJ; Restrepo-Rodriguez LF; Rothlisberger S
Acta Biochim Pol; 2020 Dec; 67(4):475-483. PubMed ID: 33284559
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and hsp90 inhibitor resistances.
Arolla RG; Malladi S; Bhaduri U; Gayatri MB; Pattamshetty P; Mohan V; Katika MR; Madhava Reddy AB; Satyanarayana Rao MR; Vudem DR; Kancha RK
Biochem Biophys Res Commun; 2021 Jan; 534():461-467. PubMed ID: 33246559
[TBL] [Abstract] [Full Text] [Related]
9. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
10. Metabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells.
Allende-Vega N; Villalba M
Sci Rep; 2019 Apr; 9(1):5637. PubMed ID: 30948782
[TBL] [Abstract] [Full Text] [Related]
11. [Expression and Significance of PD-L1, hsp90 and hsp90α in Serum of Patients with Acute leukemia].
Ma XJ; Zhang FH; Sun L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1384-1389. PubMed ID: 29070112
[TBL] [Abstract] [Full Text] [Related]
12. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract] [Full Text] [Related]
13. hsp90 - a potential prognostic marker in CML.
Záčková M; Moučková D; Lopotová T; Ondráčková Z; Klamová H; Moravcová J
Blood Cells Mol Dis; 2013 Mar; 50(3):184-9. PubMed ID: 23190580
[TBL] [Abstract] [Full Text] [Related]
14. miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia.
Liu X; Zou L; Zhu L; Zhang H; Du C; Li Z; Gao C; Zhao X; Bao S; Zheng H
Leuk Res; 2012 Sep; 36(9):1098-104. PubMed ID: 22677230
[TBL] [Abstract] [Full Text] [Related]
15. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Quintás-Cardama A; Qiu YH; Post SM; Zhang Y; Creighton CJ; Cortes J; Kornblau SM
Cancer; 2012 Nov; 118(21):5283-92. PubMed ID: 22517119
[TBL] [Abstract] [Full Text] [Related]
16. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.
Yamada O; Ozaki K; Akiyama M; Kawauchi K
Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124
[TBL] [Abstract] [Full Text] [Related]
17. c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway.
Oshikawa G; Nagao T; Wu N; Kurosu T; Miura O
J Biol Chem; 2011 Sep; 286(35):30263-30273. PubMed ID: 21768087
[TBL] [Abstract] [Full Text] [Related]
18. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.
Yu W; Wang J; Jin J; Qian W; Qian J; Cheng Y; Wang L
Leuk Res; 2011 Sep; 35(9):1212-8. PubMed ID: 21632108
[TBL] [Abstract] [Full Text] [Related]
19. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.
Mandawat A; Fiskus W; Buckley KM; Robbins K; Rao R; Balusu R; Navenot JM; Wang ZX; Ustun C; Chong DG; Atadja P; Fujii N; Peiper SC; Bhalla K
Blood; 2010 Dec; 116(24):5306-15. PubMed ID: 20810927
[TBL] [Abstract] [Full Text] [Related]
20. The synthetic heat shock protein 90 (hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
Tong WG; Estrov Z; Wang Y; O'Brien S; Faderl S; Harris DM; Van Pham Q; Hazan-Halevy I; Liu Z; Koch P; Kantarjian H; Keating MJ; Ferrajoli A
Invest New Drugs; 2011 Dec; 29(6):1206-12. PubMed ID: 20533075
[TBL] [Abstract] [Full Text] [Related]
[Next]
